Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography

Neuroscience Letters

Volumn 285, Issue 2, 2000, Pages 107-110

  Krause, Klaus Henning ^a   Dresel, Stefan H ^b   Krause, Johanna ^c   Kung, Hank F ^d   Tatsch, Klaus ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Outpatient Clin Psychiat/P   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adult; Attention deficit hyperactivity disorder; Dopamine transporter; Methylphenidate; Single photon emission computed tomography; TRODAT 1

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHYLPHENIDATE; MIDDLE AGED; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0034640146     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01040-5     Document Type: Article

References (20)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn., American Psychiatric Association, Washington, D.C., 1994.
2. Casey B., Castellanos F., Giedd J., Marsh W., Hamburger S., Schubert A., Vauss Y., Vaituzis A., Dickstein D., Sarfatti S., Rapoport J. lmplication of right frontostriatal circuitry in response inhibition and attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry. 36:1997;374-383.
3. Castellanos F., Giedd J., Marsh W., Hamburger S., Vaituzis A., Dickstein D., Sarfatti S., Vauss Y., Snell J., Lange N., Kaysen D., Krain A., Ritchie G., Rajapakse J., Rapoport J. Quantitative brain magnetic resonance imaging in attention deficit hyperactivity disorder. Arch. Gen. Psychiatry. 53:1996;607-616.
4. Cook E.H., Stein M.A., Krasowski M.D., Cox N.J., Olkon D.M., Kieffer J.E., Leventhal B.L. Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56:1995;993-998.
5. Daly G., Hawi Z., Fitzgerald M., Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry. 4:1999;192-196.
6. Dougherty D.D., Bonab A.A., Spencer T.J., Rauch S.L., Madras B.K., Fischman A.J. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet. 354:1999;2132-2133.
7. Dresel S.H.J., Kung M.-P., Plössl K., Meegalla S.K., Kung H.F. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. Eur. J. Nucl. Med. 25:1998;31-39.
8. Ernst M., Zametkin A.J., Matochik J.A., Jons P.H., Cohen R.M. DOPA decarboxylase activity in attention deficit hyperactivity disorder in adults, A [fluorine-18] fluorodopa positron emission tomographic study. J. Neurosci. 15:1998;5901-5907.
9. Gatley S.J., Volkow N.D., Gifford A.N., Fowler J.S., Dewey S.L., Ding Y.S., Logan J. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacol. (Berl.). 146:1999;93-100.
10. Kung H.F., Kim H.-J., Kung M.-P., Meegalla S.K., Plössl K., Lee H.-K. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur. J. Nucl. Med. 23:1996;1527-1530.
11. Lou H., Henriksen L., Bruhn P. Focal cerebral hypoperfusion in children with dysphoria and/or attention deficit disorder. Arch. Neurol. 41:1984;825-829.
12. Lou H., Henriksen L., Bruhn P., Borner H., Bieber Nielson J. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch. Neurol. 46:1989;48-52.
13. Matochik J., Liebenauer L., King A., Szymanski H., Cohen R., Zametkin A. Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. Am. J. Psychiatry. 151:1994;658-664.
14. Mozley P., Stubbs J., Plössl K., Dresel S., Barraclough E., Alavi A., Araujo L., Kung H. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. J. Nucl. Med. 39:1998;2069-2076.
15. Rubia K., Overmeyer S., Taylor E., Brammer M., Williams S.C., Simmons A., Bullmore E.T. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am. J. Psychiatry. 156:1999;891-896.
16. 3H]Threo (+/-)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J. Neurochem. 45:1985;1062-1070.
17. Sieg K., Gaffney G., Preston D., Hellings J. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder. Clin. Nucl. Med. 20:1995;55-60.
18. Vaidya C.J., Austin G., Kirkorian G., Ridlehuber H.W., Desmond J.E., Glover G.H., Gabrieli J.D.E. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc. Natl. Acad. Sci. USA. 95:1998;14494-14499.
19. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry. 155:1998;1325-1331.
20. Zametkin A., Nordahl T., Gross M., King A., Semple W., Rumsey J., Hamburger S., Cohen R. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. New Engl. J. Med. 323:1990;1361-1366.